Patients gained an average of 5.6% in lean body
mass during the Allurion Program
Separate studies of patients on GLP-1 therapy
report an average lean mass loss of 11%1
Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to
ending obesity, today announced the publication of a study
demonstrating an average lean mass gain of 5.6% in patients with an
average weight loss of 14% at four months on the Allurion Program.
Vital signs and physical activity were tracked in real-time with
the Allurion App, Connected Scale, and Health Tracker, and
follow-up was provided through the AI-powered Allurion Virtual Care
Suite.
In the study, 571 patients across three obesity centers treated
with the Allurion Program reduced their weight on average by 13.9kg
from 97.9kg to 84.0kg in just four months. Over that same period,
lean mass—which includes muscle mass—increased by 2.8kg on average
from 49.8kg to 52.6kg.
Higher activity patients, walking more than 8,000 daily steps on
average, achieved higher weight loss (15.6kg on average, from
97.7kg to 82.1kg) and gained more lean mass (increased by 2.8kg on
average from 50.9kg to 53.7kg) than their lower activity
counterparts who achieved a weight loss of 13.6kg on average, from
98.2kg to 84.6kg, and whose lean mass increased by 1.8kg on
average, from 49.5 to 51.3kg.
All patients experienced significant reductions in body fat
percentage, decreasing from 32.7% to 27.9% in just 4 months.
Previous studies evaluating body composition changes in patients
treated with GLP-1s have demonstrated that lean body mass losses
are common, ranging from 3-11% lean mass reductions after around a
year of treatment. Importantly, these studies did not incorporate
any real-time monitoring of body composition or personalized
approaches to promote lean mass preservation or muscle mass
gain.1,2
“Historically, weight loss has come at the expense of lean
muscle mass, the maintenance of which is critical to overall
health. These results demonstrate just the opposite, providing
evidence that it is possible to lose significant amounts of weight
while maintaining, and even increasing, lean body mass,” said Dr.
Shantanu Gaur, Founder and CEO of Allurion. “We believe that this
data underscores the impact of real-time monitoring of body
composition and personalized recommendations through our AI-powered
Virtual Care Suite. In fact, we believe that using Allurion’s AI
platform with other modalities—including GLP-1s, where muscle mass
loss is a significant risk—may be a promising path forward.”
Sources: 1. Jastreboff AM, Aronne LJ,
Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of
Obesity. N Engl J Med. 2022;387(3):205-216.
doi:10.1056/NEJMoa2206038. 2. Wilding JPH, Batterham RL, Calanna S,
et al. Once-Weekly Semaglutide in Adults with Overweight or
Obesity. N Engl J Med. 2021;384(11):989-1002.
doi:10.1056/NEJMoa2032183
About Allurion
Allurion is dedicated to ending obesity. The Allurion Program is
a weight loss platform that features the Allurion Gastric Balloon,
the world’s first and only swallowable, procedure-less intragastric
balloon for weight loss, and offers access to the Allurion Virtual
Care Suite, including the Allurion Mobile App for consumers,
Allurion Insights for health care providers featuring the Coach
Iris AI Platform, and the Allurion Connected Scale. The Allurion
Virtual Care Suite is also available to providers separately from
the Allurion Program to help customize, monitor and manage weight
loss therapy for patients regardless of their treatment plan:
gastric balloon, surgical, medical or nutritional. The Allurion
Gastric Balloon is an investigational device in the United
States.
For more information about Allurion and the Allurion Virtual
Care Suite, please visit www.allurion.com
Allurion is a trademark of Allurion Technologies, Inc. in the
United States and countries around the world.
Forward-Looking Statements
This press release may contain certain forward-looking
statements within the meaning of the U.S. federal and state
securities laws. These forward-looking statements generally are
identified by the words “believe,” “project,” “expect,”
“anticipate,” “estimate,” “intend,” “strategy,” “future,”
“opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,”
“will continue,” “will likely result,” and similar expressions and
include statements regarding the ability of the Allurion Program,
including the VCS, to improve patient and clinical outcomes,
including outcome improvements over time, the impact of a behavior
change coaching skills course, and the impact of gLP-1s on the
Allurion Program. Forward-looking statements are predictions,
projections and other statements about future events that reflect
the current beliefs and assumptions of Allurion’s management based
on information currently available to them and, as a result, are
subject to risks and uncertainties. Many factors could cause actual
future results or developments to differ materially from the
forward-looking statements in this communication, including but not
limited to (i) the ability of Allurion to obtain and maintain
regulatory approvals for and successfully commercialize the
Allurion Program, including the Allurion Balloon and the VCS, (ii)
the timing of, and results from, our clinical studies and trials,
(iii) the evolution of the markets in which Allurion competes, (iv)
the ability of Allurion to defend its intellectual property, (v)
the impact of the COVID-19 pandemic, the Russia and Ukraine war,
and the Israel-Hamas conflict on Allurion’s business, (vi)
Allurion’s expectations regarding its market opportunities,
including those for the VCS platform, and (vii) the risk of
economic downturns and a changing regulatory landscape in the
highly competitive industry in which Allurion operates. The
foregoing list of factors is not exhaustive. You should carefully
consider the foregoing factors and the other risks and
uncertainties described in the “Risk Factors” section of Allurion’s
Annual Report on Form 10-K filed on March 26, 2024 (as subsequently
amended) and other documents filed by Allurion from time to time
with the U.S. Securities and Exchange Commission. These filings
identify and address other important risks and uncertainties that
could cause actual events and results to differ materially from
those contained in the forward-looking statements. Forward-looking
statements speak only as of the date they are made. Readers are
cautioned not to put undue reliance on forward-looking statements,
and Allurion assumes no obligation and does not intend to update or
revise these forward-looking statements, whether as a result of new
information, future events, or otherwise. Allurion does not give
any assurance that it will achieve its expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240620790388/en/
Global Media Cedric Damour PR Manager +33 7 84 21 02 20
cdamour@allurion.com
Investor Contact Mike Cavanaugh, Investor Relations ICR
Westwicke (617) 877-9641 mike.cavanaugh@westwicke.com
Allurion Technologies (NYSE:ALUR)
Historical Stock Chart
From Nov 2024 to Dec 2024
Allurion Technologies (NYSE:ALUR)
Historical Stock Chart
From Dec 2023 to Dec 2024
